Physician profile
Sam Mazj
NPI 1043287378
$95,554.18
in general payments reported to CMS, 2019-2025
54 companies · $16K in 2025
The $16K reported for 2025 was more than what 91% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $3,724 · 2021: $6,326 · 2022: $7,723 · 2023: $13K · 2024: $26K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $43K · Travel and Lodging: $5,393 · Food and Beverage: $3,814 · Consulting Fee: $2,350 · Education: $240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $42,888.75 |
| Travel and Lodging | $5,392.81 |
| Food and Beverage | $3,814.03 |
| Consulting Fee | $2,350.00 |
| Education | $240.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $38,072.15 | 2019-2025 | Darzalex, Tecvayli, Carvykti |
| Astrazeneca Pharmaceuticals Lp | $24,718.93 | 2019-2025 | Calquence, Imfinzi, Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $20,823.66 | 2019-2022 | |
| Caris Mpi, INC. | $1,126.58 | 2025 | Mi Cancer Seek |
| Pfizer INC. | $1,010.51 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $910.36 | 2019-2025 | Opdivo |
| Seagen INC. | $732.72 | 2019-2022 | |
| Amgen INC. | $641.02 | 2019-2022 | |
| Abbvie INC. | $639.49 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $638.05 | 2019-2021 | |
| Genentech USA, INC. | $615.60 | 2019-2022 | |
| Lilly USA, LLC | $474.22 | 2019-2023 | |
| Daiichi Sankyo INC. | $450.99 | 2019-2025 | Enhertu |
| Clovis Oncology, INC. | $448.60 | 2019-2022 | |
| Astellas Pharma US INC | $398.82 | 2019-2021 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sam Mazj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.